ABSTRACT
INTRODUCTION P
TP SHP-1 (SH-PTP1, PTP1C, PTPN6, hematopoietic cells PTP (Matthews et al., 1992; Yi et al., 1992) and PTP SHP-2 (SH-PTP2, PTP2C, PTPN11) (Ahmad et al., 1993) form a group of intracellular nontransmembrane tyrosine phosphatases containing two SH2 domains and one catalytic domain (Ahmad et al., 1993) . SH2 domains direct the association of these PTP with specific phosphotyrosine containing sites on activated growth factor receptors and certain cytoplasmic signaling proteins (Pawson and Gish, 1992) . PTP SHP-1 and SHP-2 are active in different signaling processes and provide dephosphorylation of tyrosines of cell surface receptors (Lechleider et al., 1993) , adaptor molecules (Kharitonenkov et al., 1997) , and some cytoplasmic proteins in signaling cascades (Pawson, 1995) .
PTP SHP-1 and SHP-2 are involved in NFkB activation, but their effects on this process are different. PTP SHP-1 is a negative regulator of NFkB activation. The activation of NFkB is higher in the cells from PTP SHP-1 deficient "motheaten" mutant mice (Khaled et al., 1998; Massa and Wu, 1998) . These animals have a high percentage of early mortality due to different inflammatory disorders (Sidman et al., 1984) . In contrast with PTP SHP-1, PTP SHP-2 is a positive regulator of NFkB activation. NFkB activation by TNF and IL-1 was suppressed in the fibroblasts from the mice with knockout of both alleles of PTP SHP-2 gene (You et al., 2001) . We can predict that the ability of different factors to stimulate NFkB should depend on correlation of activities of these PTP in the cells. The ability of PTP SHP-1 and SHP-2 to regulate NFkB activation makes these phosphatases an attractive target for the treatment of inflammation and cancer.
The recruitment and the activation of PTP in signaling require the presence of adapter molecules. In some processes the role of these adapter molecules play inhibitory receptors, which contain within their cytoplasmic domains tyrosine residues re-sponsible for binding and activation of SH2 domain containing PTP (Cambier, 1997) . One of the inhibitory receptor is signal regulatory protein (SIRPa) (Kharitonenkov et al., 1997) . This transmembrane protein is present in many tissues and cell types, and is a substrate and the adapter for PTP SHP-1 (Veillette et al., 1998) and PTP SHP-2 (Kharitonenkov et al., 1997) .
The changes in the amount and activities of SIRPa can modify the efficiency of signaling processes. The overexpression of wild-type SIRPa suppressed the signaling from growth factor receptors (Kharitonenkov et al., 1997; Wu et al., 2000) and from growth hormone receptor (Stofega et al., 2000) . The expression of dominant negative form of SIRPa (GSE2-1) stimulated NFkB activity and made the cells resistant to TNF specific apoptosis (Neznanov et al., 2003) .
In present studies, we examined the mechanisms of SIRPa and GSE2-1 activities in the process of NFkB activation in epithelial 293 cells. These cells contain both forms of PTP SHP-1 and SHP-2. NFkB activation in these cells depends on correlation in their activities. The ability of GSE2-1 to activate NFkB in 293 cells is the result of its interference with PTP SHP-1.
MATERIALS AND METHODS

Cells and transfection
HeLa, 293, and primary human fibroblasts MRC5 cell lines were cultured in Dulbecco modified Eagle medium (Gibco BRL, Frederick, MI) supplemented with 10% fetal calf serum. The transfections of 293 cells were conducted with Lipofect-AMINE PLUS reagent (Invitrogen, San Diego, CA/Gibco BRL) according to the provider protocols.
Plasmids
The expression vectors for GSE2-1, GSE1FSIRP, wild-type SIRPa, and SIRP4Y were described before (Wu et al., 2000; Neznanov et al., 2003) cDNA for human PTP SHP-1 was recloned from EST clone (IMAGE ID# 4854521) into pcDNA3 expression vector. DnFlagSHP-1His was generated from original PTP SHP-1 cDNA. Cysteine 453 in the active center of this molecule was substituted by serine (C453S) with PCR reaction. This substrate trapping dominant negative mutant (Timms et al., 1998) was complemented with Flag sequence at its N end and six histidine residues at its C end. The cDNA for human PTP SHP-2 was recloned from EST clones (IMAGE ID#4452236 and #6066834) into a pcDNA3 expression vector. The ability of the vectors to express proteins was tested by Western blotting.
RT PCR
Total RNA was purified from 293, HeLa, and primary human fibroblasts MRC5. We used antisense oligonucleotide primers to synthesize the first strand of cDNAs: for human PTP SHP-1 transcriptional variant 3 59-CTGAGGACAGCAC-CGCTCACT-39 and for human PTP SHP-2 transcriptional variant 1 59-TTCTGTGCTGAAGTTTTGGCAGGTTTTC-3 9. To complete the PCR reaction we used sense oligonucleotide primers: 59-TCATTGAAACCACTAAGAAGA-3 9 (PTP SHP-1) and 59-AGCGACCCTGGGGGCGTGCTGGAC-3 9 (PTP SHP-2). PCR products were treated with RNase A before loading on the gel.
NFkB luciferase reporter assay
The efficiency of NFkB transcriptional activity was estimated using reporter plasmid containing a minimal promoter of c-fos gene combined with two oligonucleotides corresponding to NFkB binding sites from HIV LTR (Neznanov et al., 2003) . The efficiency of transfection in luciferase assay experiments was estimated by b-galactosidase expression from a cotransfected 50 ng of pcDNA3-lacZ plasmid. The results of luciferase assays were normalized according to b-galactosidase activity. The luciferase and b-galactosidase activities were measured with corresponding kits (Promega, Madison, WI) according to the provider protocol.
NFkB gel shift assay
The protocol of experiments was described in our previous publication (Neznanov et al., 2001) . A double-stranded oligonucleotide probe comprising an NFkB-binding region of the mouse B cell-light chain enhancer (59-AGT TGA GGG GAC TTT CCC AGG C-39, Promega) was end labeled with [g-32 P] ATP following the manufacturer's recommended protocol. The nuclear protein extracts were purified from five million of 293 cells transfected with corresponding expression vectors 24 h before extract purification. The level of transfection was estimated by cotransfection with green fluorescent protein (GFP) expression vector. The level of transfection varied between 60 and 80%. The NFkB activation by TNF was done for 1 h before protein purification.
Proteins affinity purification
The polyhistidine-containing proteins and their interactors were affinity purified on Ni-NTA spin columns (Qiagen, Chatsworth, CA). 3 3 10 6 of 293 cells transfected with expression vectors for GSE2-1 or GSE1FSIRP (Neznanov et al., 2003) and dnFlagSHP-1His were collected on the ice and resuspended in 500 ml of lysis buffer (50 mM Na-phosphate buffer, pH7.5; 300 mM NaCl; 10 mM imidazole). Cells were sonicated on ice. We centrifuged the lysate at 10,000 3 g for 6 min at 4°C. Supernatant was fractionated on Ni-NTA spin column according to the provider protocol. We used the elution buffer with 250 mM of imidazole to collect polyhistidine containing proteins from the column. The proteins from eluate were analyzed by Western immunoblotting procedure.
Western immunoblotting
Total protein extracts from mouse brain, kidney, and small intestine were prepared in 1 ml of RIPA buffer (150 mM NaCl, 1% SDS, 10 mM Tris, pH8.0, 1% sodium deoxycholate, 1% NP-40) with the protease inhibitor cocktail (Sigma, St. Louis, MO). The total protein extracts from 2 3 10 6 of 293, HeLa, primary human fibroblasts MRC5, or 293 cells overexpressing wild-type PTP SHP-1, PTP SHP-2, GSE2-1, GSE1FSIRP (Neznanov et al., 2003) , and dnFlagSHP-1His proteins in 100 ml of RIPA buffer with the protease inhibitor cocktail (Sigma) were separated by electrophoresis in 4-20% precast polyacrilamide gels with SDS (Novex, San Diego, CA), and transferred to nylon PVDF membranes Hybond P (Amersham, Arlington Heights, IL) (ECL, Amersham). Nylon filters with proteins were incubated with primary rabbit polyclonal anti-SHP-1, anti-SHP-2, anti-SIRPa/SHPS-1 antibodies (Upstate Biotechnology, Lake Placid, NY), or anti-FLAG antibodies (Sigma). After extensive washing in PBS, the immune complexes were visualized by enhanced chemiluminescence ECL (Perkin-Elmer Life Sciences, Norwalk, CT). The control of protein loading in the gel was done with antiactin goat polyclonal antibodies (Santa Cruz Biotechnologies, San Cruz, CA). HRP-conjugate secondary antirabbit, antigoat, and antimouse antibodies were purchased from Santa Cruz.
RESULTS
Epithelial cells 293 contain SHP-1 and SHP-2 protein tyrosine phosphatases
Protein tyrosine phosphatase (PTP) SHP-2 (PTP2Ci, PTPN11) is a widely expressed PTP (Ahmad et al., 1993) . PTP SHP-1 (hematopoietic cell phosphatase, SH-PTP1, PTP1C, and PTPN6) is more abundant in hematopoietic cell lines (Yi et al., 1992) , but it was also detected in different epithelial cell lines like A431 (Banville et al., 1995; Tomic et al., 1995; Keilhack et al., 2000) and HeLa (Banville et al., 1995) . The 293 cell line is a permanent line of primary human embryonic kidney epithelial cells transformed by human adenovirus type 5 DNA. We used these cells in our previous experiments with a dominant negative mutant form of SIRPa (GSE2-1) (Neznanov et al., 2003) . PTP SHP-1 and SHP-2 form a complex with phosphorylated tyrosines of SIRPa and use this protein as their substrate (Kharitonenkov et al., 1997; Veillete et al., 1998) . We analyzed 293 cells for the presence of PTP SHP-1 and SHP-2 to identify that of these PTP can be the target for GSE2-1. The results of this analysis are present on Figure 1 . According to RP PCR with the primers specific for 39 coding ends of PTP SHP-1 and SHP-2 cDNAs, epithelial cells, HeLa and 293, express both types of tested PTP. Human lung fibroblasts MRC5 express predominantly PTP SHP-2 (Fig. 1A) . cDNA for PTP SHP-1 can be seen in fibroblasts only after additional rounds of PCR (data not shown). These results are in good correlation with the Western blotting analysis for proteins from epithelial cells, HeLa and 293, and human primary fibroblasts. Both types of tested PTP can be detected in epithelial cells, but only PTP SHP-2 can be seen in fibroblast cells (Fig.  1B) . PTP SHP-1 is abundant protein in mouse small intestine and kidney (Fig. 1B) . These tissues contain simple epithelial cells, in contrast with the brain, where PTP SHP-1 is less abundant (Fig.  1B) (Abe and Oshima, 1990) .
Overexpression of PTP SHP-1 and SHP-2 has opposite effect on NFkB activity in 293 cells
PTP SHP-1 and SHP-2 have different roles in the activation of NFkB. PTP SHP-1 has a negative effect on NFkB activation by different stimulus (Massa and Wu, 1998) , and PTP SHP-2 supports the NFkB activation by TNF and IL-1 (You et al., 2001) . How does the coexpression of two types of PTP regulate NFkB activity in 293 cells? To answer this question we overexpressed PTP SHP-1 and PTP SHP-2 and their combination in this cell line. The results of these experiments are present on Figure 2A . The overexpression of PTP SHP-1 slightly suppressed basic level of NFkB activity and decreased TNFspecific activation of NFkB about three times. PTP SHP-2 exists in different forms that depend on alternative splicing. We used the long variant 1 with 137 amino acids on the C end after the active center of the molecule ( Fig. 2A ) and the short variant 3 with the active center on the C end of the molecule (data not shown). The results of experiments with any tested form of PTP SHP-2 were similar. The overexpression of PTP SHP-2 significantly stimulated NFkB-specific luciferase expression and increased TNF-specific activation of NFkB. The coexpression of PTP SHP-1 with SHP-2 suppressed the stimulating activity of SHP-2 in NFkB-specific luciferase assay and decreased the ability of TNF and SHP-2 to activate NFkB ( Fig.  2A) . We tested the expression of all PTP by Western blotting with corresponding antibodies (Fig. 2B) .
Overexpression of SIRPa decreases the activities of both types of PTP in 293 cells
SIRPa makes the complex with PTP SHP-1 and SHP-2, and is their substrate when phosphorylated by tyrosines in ITIM motives (Kharitonenkov et al., 1997; Veillete et al., 1998) . The overexpression of SIRPa suppressed the activities of growth factors (Kharitonenkov et al., 1997) and EGF specific activation of PI3K (Wu et al., 2000) . The tyrosine-less mutant form of SIRPa (SIRP4Y) did not have this suppression activity (Kharitonenkov et al., 1997; Wu et al., 2000) . Can overexpression of SIRPa interfere with activities of PTP SHP-1 and SHP-2 in the process of TNF specific NFkB activation? The exogenous level of SIRPa in 293 cells is rather low, and expression of SIRPa in the pcDNA3 vector can create significant overexpression of this protein in 293 cells (Neznanov et al., 2003) . Coexpression of SIRPa with PTP SHP-1 in 293 cells slightly decreased suppressive SHP-1 activity in NFkB-dependent luciferase assays (Fig. 3A) . The overexpression of SIRPa had a stronger effect in combination with PTP SHP-2 overexpression (Fig. 3B) . The overexpression of SIRPa, in combination with PTP SHP-2, totally suppressed stimulating activity of PTP SHP-2 in NFkB-specific luciferase assay. It strongly inhibited combinatorial activities of PTP SHP-2 and TNF in this assay (Fig. 3B) . The tyrosine-less mutated form SIRP4Y (Kharitonenkov et al., 1997; Wu et al., 2000) did not have this inhibitory activity.
PTP SHP-1 interferes with activity of dominant negative form of SIRPa
The expression of GSE2-1, a dominant negative form of SIRPa, in 293 cells strongly increases NFkB activity by stimulating PI3K/Akt pathway (Neznanov et al., 2003) . Two possible mechanisms can be proposed to explain GSE2-1 ability to activate NFkB in epithelial cells. PTP SHP-1 and SHP-2 can form the complex with wild-type SIRPa (Kharitonenkov et al., 1997; Villete et al., 1998) , and these two PTP can be the targets for GSE2-1. GSE2-1 can increase stimulating activity of PTP SHP-2 in 293 cells or can decrease inhibitory activity of SHP-1 in the process of NFkB activation. We coexpressed GSE2-1 with each of these PTP and analyzed NFkB-specific The overexpression of SIRPa (500 ng for transfection) strongly suppresses the positive effect of PTP SHP-2 on NFkB activity. All assays were done as described in the legend to Figure 2A . Notice that SIRP4Y did not suppress PTP SHP-2 activity in NFkB specific assay. transcription in the luciferase assay to distinguish between two proposed mechanisms. We detected the ability of additional amounts of PTP SHP-1 to interfere with NFkB stimulating activity of GSE2-1 (Fig. 4A ). In contrast with these results, the additional expression of PTP SHP-2 did not increase the activation of NFkB by GSE2-1 (Fig. 4A) . The overexpression of the dominant negative form of PTP SHP-1 had an influence similar with GSE2-1 on NFkB-specific transcriptional activation (Fig. 4B) and on the translocation of NFkB into the nucleus (Fig. 4C) .
Dominant negative mutant of SIRPa forms a complex with PTP SHP-1
Dominant negative mutant of SIRPa, GSE2-1, and PTP SHP-1 can interfere with each other's activities in NFkB-specific luciferase assays. Is this interference a result of direct interaction between these two proteins? We used affinity copurification of polyhistidine TAG containing PTP SHP-1 with other proteins to analyze this possibility. SIRPa is the substrate for PTP SHP-1. Dephosphorylation of SIRPa tyrosines decreases the stability of the complex between PTP and SIRPa (Kharitonenkov et al., 1997) . To avoid this problem, the complexes between PTP and their substrates should be purified in the presence of phosphatase inhibitors or mutant forms of PTP without phosphatase activity. We used cysteine-to-serine substitution in the active center of PTP SHP-1 (C453S) to make protein, which can create stable complexes with PTP-SHP-1 substrates (substrate-trapping mutant) (Timms et al., 1998) , like SIRPa. This dominant negative form of PTP SHP-1 has additional polyhistidine TAG at its C end for affinity purification and FLAG on its N end for Western blotting detection (dnFlagSHP1His). The protein extracts were purified in nondenaturing conditions from 293 cells transitory transfected with vectors expressing dnFlagSHP-1His and GSE2-1 or GSE1FSIRP. The mutated form of GSE2-1, GSE1FSIRP, with lower activity (Neznanov et al., 2003) was used as a negative control. Polyhistidine containing proteins were purified on Ni-column and analyzed by Western blotting with antibodies against SIRPa for GSE and anti-FLAG antibodies for dnFlagSHP-1His. The results of this experiment are shown on Figure 5 . GSE2-1 can be found in the complex with dnFlagSHP-1His. It can be copurified with dnFlagSHP-1His on Ni-column. The mutated form of GSE2-1 with lower NFkB activating potential has a lower affinity to dnFlagSHP-1His.
DISCUSSION
PTP SHP-1 and SHP-2 have different patterns of expression in different tissues. Many lines of hematopoietic cells express predominantly PTP SHP-1, which play an important negative regulatory role in the process of hematopoietic cell growth, differentiation, and antigen response (Berg et al., 1999; Bittorf et al., 1999; Coggeshall et al., 2002) . PTP SHP-2 is widely expressed in many tissues, and plays a positive regulatory role in many signaling processes (Qu, 2000; Wu et al., 2001; MacGillivray et al., 2003; Tartaglia et al., 2003) . The 293 cell line, like other epithelial cells, expresses both forms of PTP. As a result, the efficiency of the signaling in these cells de- All assays were done as described in the legend to Figure 2A .
(C)
The overexpression of GSE2-1, SHP-2, and dnSHP-1 in 293 cells stimulates the translocation of NFkB into the nucleus. The results of gel shift assay. Ten micrograms of nuclear protein extracts from 293 cells transfected for 24 h with corresponding vectors were used for gel shift assay with NFkB-specific 32 P-labeled doublestranded oligonucleotide probe. The cells from the lines 2 and 6 were treated with TNF for 1 h before protein nuclear extract purification. According to the cotransfection with GFP expression vector, the level of transfection was from 60 to 80%.
pends on the correlation between the activities of PTP SHP-1 and PTP SHP-2. The signaling processes leading to NFkB activation in 293 cells can be modified by the changes in the proportion between PTP SHP-1 and PTP SHP-2. The overexpression of PTP SHP-1 in our experiments only slightly changed the basic level of NFkB activation and decreased the TNF-specific NFkB activation two to three times. In contrast with these results, the overexpression of PTP SHP-2 in 293 cells stimulated six to eight times the basic level of NFkB activity, and had an additive effect on TNF-specific NFkB activation. The cotransfection of 293 cells with the combination of PTP SHP-2 and SHP-1 leads to the decrease of NFkB-stimulating SHP-2 activity. These results demonstrate that PTP SHP-1 and SHP-2 compete with each other during the activation of NFkB, and that in 293 cells SHP-1 activity dominates over SHP-2 activity. SIRPa is the adapter and substrate of PTP SHP-1 and SHP-2 (Kharitonenkov et al., 1997; Veillette et al., 1998) . The tyrosine residues in the cytoplasmic part of SIRPa can be phosphorylated by the tyrosine protein kinase (TPK) activities of growth factor receptors (Kharitonenkov et al., 1997) or PTK like src (Oshima et al., 2002) . When SIRPa is phosphorylated, it attaches PTP SHP-1 or SHP-2 to the complex with growth factor receptors or other substrates of PTP (Cambier, 1997; Cant and Ullrich, 2001) . The overexpression of SIRPa in fibroblasts suppresses the ability of growth factors to stimulate 3 H-thymidine incorporation (Kharitonenkov et al., 1997) . We showed in our recent publication that overexpression of SIRPa in epithelial cells, HeLa and 293, slightly suppresses NFkB activity in these cells (Neznanov et al., 2003) . In contrast with these results, the effect of SIRPa overexpression was stronger when we contransfected PTP SHP-2 expression vector with SIRPa expression vector. SIRPa totally suppressed strong NFkB stimulating activity of PTP SHP-2 in these experiments (Fig. 3B) . The overexpression of SIRPa changed the activity of PTP SHP-1 less efficiently (Fig. 3A) . Tyrosine less mutated form of SIRPa (SIRP4Y) (Kharitonenkov et al., 1997; Wu et al., 2000) did not change PTP SHP-2 activity because of the inability to make a complex with PTP.
GSE2-1, a dominant negative form of SIRPa, has a different effect on PTP SHP-1 and SHP-2 activities. Overexpression of GSE2-1 in 293 cells stimulates NFkB-related expression of luciferase reporter gene (Fig. 4A) (Neznanov et al., 2003) . We showed that a combination of expression of GSE2-1 with increasing amounts of PTP SHP-2 expressing vector did not increase NFkB activity in the luciferase assay (Fig. 4A ). In contrast with these results, the coexpression of GSE2-1 with increasing amounts of PTP SHP-1-expressing vector decreased stimulatory activity of GSE2-1 in NFkB-dependent luciferase assay (Fig. 4A) . These results support the mechanism of GSE2-1 function as an inhibitor of negative PTP SHP-1 activity in the process of NFkB activation.
Why does GSE2-1 preferably interact with PTP SHP-1 but not SHP-2? One of the possible explanations could be different location of PTP SHP-1 and SHP-2 in epithelial cells. Recently, PTP SHP-1 was localized mainly into the nucleus of primary intestinal epithelial cells (Duchesne et al., 2003) . GSE2-1, in contrast with wild type SIRPa, does not have a signal for membrane localization (Neznanov et al., 2003) , and can interact with PTP SHP-1 in different areas of the cell. The interaction between GSE2-1 and PTP SHP-1 (Fig. 5) can titrate phosphatase from its complexes with other targets. The negative activity of SHP-1 in signaling can be blocked up by this GSE2-1-dependent titration.
What is the negative regulatory role of PTP SHP-1 in PI3K/Akt signaling? The regulatory subunit of PI3K was shown to be the substrate of PTP SHP-1 (Cuevas et al., 1999) . The inhibitory activity of p85 is relieved by occupancy of the NH(2)-terminal SH2 domain of p85 by phosphorylated tyrosine. The Src family kinases phosphorylate tyrosine 688 in p85. This process can be reversed by the activity of the p85-associated SH2 domain-containing phosphatase PTP SHP-1. It was demonstrated that phosphorylation of the downstream PI3K target Akt is increased in cells lacking PTP SHP-1, implicating phosphorylation of p85 in the regulation of PI3K activity (Cuevas et al., 2001) . Wild-type PTP SHP-1 induces dephosphorylation of p85 PI3K and decreases phosphorylation of Ser-473 in Akt, a process dependent on PI3K activity (Cuevas et al., 1999) . According to these publications, dephosphorylation of p85 regulatory subunit of PI3K by PTP SHP-1 provides negative regulation of the PI3K/Akt signaling. A lowered level of NFkB activation can be one of the results of this negative regulation, because PI3K/Akt signaling is necessary for NFkB activation (Ozes et al., 1999; Romashkova and Makarov, 1999) . P85 PI3K is not the only target of PTP SHP-1 in PI3K/Akt signaling. Recently, PTEN, another negative regulator of Akt signaling, was shown to be the target for src-PTK and PTP SHP-1 system (Lu et al., 2003) . The authors showed that in the presence of a functional PTEN, Src reduces the activity of PTEN, resulting in an increase in Akt phosphorylation and recruitment of Akt to the cell membrane. This suggests that functional PTEN is required for Src family kinases to mediate their effects on the PI3K pathway. PTP SHP-1 selectively binds and dephosphorilates PTEN in Src transfected cells. Both Src inhibitor and SHP-1 overexpression reverse Src-induced loss of PTEN function. Taken together, the data indicate that activated Src inhibits PTEN func-NEZNANOV ET AL. 180 FIG. 5. The GSE2-1 is in the complex with PTP SHP-1. Western blotting of Ni affinity-purified protein complexes with dnFlagSHP-1His. The protein extracts from 293 cells transfected with dnFlagSHP-1His and GSE2-1 expression vectors (1, 2) were loaded on Ni affinity column. 1-the flow-through fraction, 2-the elution by 250 mM of imidazole. The protein extracts from 293 cells transfected with dnFlagSHP-1His and GSE1FSIRP expression vectors (3, 4). 3-The flow-through fraction, 4-the elution by 250 mM of imidazole. The filter was cut after transferring of the proteins. The part of the filter with low molecular weight proteins (GSE are the proteins with molecular weight around 10 kDa) was analyzed with anti-SIRPa antibodies. The part of the filter with high molecular weight proteins (molecular weight of PTP SHP-1 is around 70 kDa) was analyzed with anti-Flag antibodies. Notice that GSE2-1 and GSE1FSIRP are of different molecular weight. They are the parts of mouse and human SIRPa.
tion, leading to alterations in signaling through the PI3K/Akt pathway. PTP SHP-1 reverses Src activity and reactivates negative regulation of Akt signaling by PTEN (Lu et al., 2003) . As a result, PTP SHP-1 acts as a negative regulator of PI3K/Akt/ NFkB signaling at least on two steps of this process. We showed that the expression of GSE2-1 stimulates NFkB activation through PI3K/Akt pathway (Neznanov et al., 2003) . GSE2-1 stimulates Akt phosphorylation, and the PI3K inhibitor (wortmannin) can suppress this process (Neznanov et al., 2003) . The titration or interference with PTP SHP-1 functions by GSE2-1 releases Akt/NFkB signaling from negative regulation by PTP. As a result, NFkB activity increases in 293 cells expressing GSE2-1. The expressions of GSE2-1 and dominant negative PTP SHP-1 have similar effects on NFkB activation (Fig. 4B) .
The role of PTP SHP-2 in NFkB activation is well documented (You et al., 2001) , but less clear than the role of PTP SHP-1. PTP SHP-2 was described as an important protein in signaling from different PTK growth factor receptors to the Ras signaling pathway (Bennett et al., 1994; Qu, 2000; Yart et al., 2003) . This protein is an important component of PI3K/Akt activation by growth factors (Wu et al., 2001) . The overexpression of SIRPa suppressed signaling from EGF receptor to PI3K (Wu et al., 2000) . Our results indicate that PTP SHP-2 can be involved in NFkB activation. The overexpression of SIRPa can titrate PTP SHP-2 from this process.
GSE2-1 interferes with PTP SHP-1 function and changes the balance between PTP SHP-1 and SHP-2 in favor of SHP-2. NFkB activity increases as a result of this change. The ability of SIRPa to modify PTP SHP-1 and SHP-2 activities makes it an attractive target for regulation of NFkB-dependent inflammation and cancer cell survival.
